NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
Bolt Biotherapeutics, Inc.
The First Affiliated Hospital of Zhengzhou University
DEKA Biosciences
Sichuan University
Sichuan University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tianjin Medical University Cancer Institute and Hospital